Hemodynamic Effects of 8-Day DL-028 and Octreotide Administration in Rats with Portal Hypertension

References

• Genecin P, Groszmann RJ. The biology of portal hypertension. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. The liver: biology and pathobiology. 3rd ed. New York: Raven Press; 1994. p. 1327–41.
   Google Scholar
• Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994;61:65–107.
   PubMedGoogle Scholar
• D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332–54.
   Google Scholar
• Ikeda M. Effect of phenoxybenzamine (POB) on portal venous pressure in patients with portal hypertension. Am J Gastroenterol 1979;71:389–94.
   PubMedGoogle Scholar
• Mills PR, Rae AP, Farah DA, Russel RI, Lorimer AR, Carter DC. Comparison of three adrenoceptor blocking agents in patients with cirrhosis and portal hypertension. Am J Gastroenterol 1984;25:73–8.
   Google Scholar
• Cummings SA, Kaumann AJ, Groszmann RJ. Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats. Hepatology 1988;8:1111–5.
   Google Scholar
• Koshy A, Sekiyama T, Hadengue A, Cerini R, Braillon A, Lebrec D. Effects of α1 and β-adrenergic antagonists and 5-hydroxytryptamine receptor antagonist on portal-systemic collateral vascular resistance in conscious rats with portal hypertension. J Gastroenterol Hepatol 1992;7:449–54.
   PubMedGoogle Scholar
• Albillos A, Lledo JL, Banares R, Rossi I, Iborra J, Calleja JL, et al. Hemodynamic effects of α-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994;20:611–7.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995;109:1257–65.
   Google Scholar
• Chern J-W, Tao P-L, Yen M-H, Lu G-Y, Shiau C-Y, Lai Y-J, et al. Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c]quinazoline derivatives: a novel class of potent and selective α1-adrenoceptor antagonists and antihypertensive agents. J Med Chem 1993;36: 2196–207.
   Google Scholar
• Huang Y-T, Lin L-C, Chern J-W, Lin H-C, Hong C-Y. Portal hypotensive effects of DL-028 and prazosin on portal hypertensive rats. Pharmacology 1998;57: 132–8.
   Google Scholar
• Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658–702.
   PubMed Web of Science ®Google Scholar
• Burroughs AK. Octreotide in variceal bleeding. Gut 1994;Suppl 3:S23–7.
   Google Scholar
• Albillos A, Colombato LA, Lee F-Y, Groszmann RJ. Octreotide ameliorates vasodilatation and Na⁺ retention in portal hypertensive rats. Gastroenterology 1993;104:575–9.
   Google Scholar
• Lin H-C, Yang MC-M, Hou M-C, Li S-M, Huang Y-T, Yu P-C, Tsai Y-T, Lee S-D. Effects of long-term administration of octreotide in portal vein stenosed rats. Hepatology 1996;23:537–43.
   Google Scholar
• Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. Br Med J 1997;315:1338–41.
   PubMedGoogle Scholar
• Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371–5.
   PubMed Web of Science ®Google Scholar
• Lebrec D. Animal models of portal hypertension. In: Okuda K, Benhamou J-P, editors. Portal hypertension: clinical and physiological aspects. Tokyo: Springer Verlag; 1991. p. 101–13.
   Google Scholar
• Huang Y-T, Cheng Y-R, Lin H-C, Hou M-C, Lee S-D, Hong C-Y. Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats. Dig Dis Sci 1998; 43:358–64.
   Google Scholar
• Lin H-C, Tsai Y-T, Yang MC-M, Lee F-Y, Hou M-C, Chen L-S, et al. Effect of octreotide on total vascular compliance in patients with post-hepatitic cirrhosis. J Hepatol 1996;24:81–7.
   Google Scholar
• Lin H-C, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991;13:213–9.
   Google Scholar
• Lin H-C, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology 1991;14:325–30.
   Google Scholar
• Lee F-Y, Colombato LA, Albillos A, Groszmann RJ. Administration of N^ω-Nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105:1464–70.
   Google Scholar
• Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248:G618–25.
   Google Scholar
• Groszmann RJ, Kravetz D, Bosch J, Glickman M, Bruix J, Bredfeldt JE, et al. Nitroglycerin improves the hemodynamic responses to vasopressin in portal hypertension. Hepatology 1982;2:757–62.
   PubMed Web of Science ®Google Scholar
• Tsai Y-T, Lay C-S, Lai K-H, Ng W-W, Yeh Y-S, Wang J-Y, et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986;6:406–9.
   Google Scholar
• Gimson aEs, Westaby D, Hayes PC, Hegarty J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986;6:410–3.
   Google Scholar
• Vachiery F, Moreau R, Gadano A, Yang S, Sogni P, Hadengue A, et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective β-blocker. Dig Dis Sci 1996;41:1722–6.
   PubMedGoogle Scholar
• Lee F-Y, Tsai Y-T, Lin H-C, Lee S-D, Hsia H-C, Lin W-J, et al. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J Hepatol 1992;15:54–8.
   Google Scholar
• Hori N, Okanoue T, Sawa Y, Itoh Y, Mori T, Takami S, et al. Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201–995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats. J Gastroenterol 1994;29:460–8.
   PubMedGoogle Scholar
• Kroeger RJ, Groszmann RJ. The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology 1985;5:425–30.
   PubMed Web of Science ®Google Scholar
• van de Casteele M, Roey GV, Nevens F, Fevery J. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996;24:1492–6.
   PubMedGoogle Scholar
• Roulot D, Gaudin C, Braillon A, Sekiyama T, Bacq Y, Lebrec D. Hemodynamic effects of a combination of clonidine and propranolol in conscious cirrhotic rats. Can J Physiol Pharmacol 1989;67:1369–72.
   PubMedGoogle Scholar
• Hadengue A, Moreau R, Cerini R, Koshy A, Lee SS, Lebrec D. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hepatology 1989;9:83–7.
   PubMedGoogle Scholar
• Moreau R, Cailmail S, Lebrec D. Effects of vasopressin on haemodynamics in portal hypertensive rats receiving clonidine. Liver 1994;14:45–9.
   Google Scholar
• Sogni P, Soupison T, Moreau R, Le Moine O, Bacq Y, Hadengue A, et al. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving β-adrenergic antagonists. J Hepatol 1994;20:548–52.
   Google Scholar
• Oberti F, Rifflet H, Maiga MY, Pilette C, Gallois Y, Douay O, et al. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepatol 1997; 26:167–73.
   PubMed Web of Science ®Google Scholar
• Avgerinos A, Armonis A, Raptis S. Somatostatin and octreotide in the management of acute variceal hemorrhage. Hepatogas-troenterology 1995;42:145–50.
   Google Scholar
• Imperiale TF, Teran JC, McCullouch AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995;109: 1289–94.
   Google Scholar
• Colombato LA, Robin M, Pomier-Layrargues G, Huet P-M. Animal models of portal hypertension. In: Holstege A, Hahn EG, Scholmerich J, editors. Portal hypertension. London: Kluwer Academic Publishers; 1995. p. 3–14.
   Google Scholar
• Møller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997;26:1026–33.
   Google Scholar
• Wang S-S, Lee F-Y, Wu S-L, Hwu C-M, Chien C-H, Lee S-D, et al. Effect of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997;26:1128–34.
   Google Scholar